Business Context and Reporting Period
This Form 8-K is a current report filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp as indicated in metadata) on December 25, 2021. The filing reports a corporate governance event: the appointment of a new director to the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the expansion of the Board of Directors from six to seven members. Effective immediately on December 25, 2021, the Board appointed Corinna E. Lathan, Ph.D. as a director. Her term is set to expire at the 2022 Annual Meeting of Stockholders.
Management Commentary and Risks
Management highlighted Dr. Lathan's qualifications to support the company's strategic direction:
- Over 20 years of experience in robotics, mobile technology, and human-technology interfaces.
- Co-founder, Board Chair, and CEO of AnthroTronix, a biomedical engineering R&D company.
- Current board member of PTC, Inc. (Nasdaq: PTC), serving on its Audit and Cybersecurity Committees.
- Academic background includes a Ph.D. in Neuroscience from MIT and prior professorships in Biomedical and Aerospace Engineering.
The filing confirms no "family relationship" exists between Dr. Lathan and existing directors or executive officers. No specific risks, contingencies, or unusual items were disclosed in this report.
Key Facts for Investor Verification
- Verify the exact date of the press release announcing the appointment (December 28, 2021) referenced in Exhibit 99.1.
- Confirm the total number of board seats following the expansion to seven.
- Review Dr. Lathan's specific committee assignments, if any, within Ekso Bionics (not explicitly stated in this text).
- Note the discrepancy between the metadata company name (Chronoscale) and the actual registrant (Ekso Bionics).